VIM and ovarian cancer: Based on our GRHL2 ChIP-seq in ovarian cancer cells10, GRHL2 binds to its own promoter, the intron 2 enhancer of CDH1, intron 1 of ZEB1, but not to VIM. It is possible that the demethylation effects of 5-azacitidine contributed to the self-activation of GRHL2, which might regulate itself directly or indirectly via downregulation of its repressor ZEB133.